Logo

VBL Therapeutics to Initiate P-II Study Evaluating VB-111 (ofranergene obadenovec) + Nivolumab in Patients with Metastatic Colorectal Cancer

Share this

VBL Therapeutics to Initiate P-II Study Evaluating VB-111 (ofranergene obadenovec) + Nivolumab in Patients with Metastatic Colorectal Cancer

Shots:

  • The focus of the study is to evaluate the safety & tolerability of the combination therapy in addition to ORR as well as immunological and histologic readouts from tumor biopsies. The clinical study will be the first study to evaluate the combination of VB-111 with a checkpoint inhibitor
  • The National Cancer Institute (NCI) will serve as an IND sponsor which has been approved by the US FDA. The study is expected to highlight the potential of VB-111 to turn “cold” colorectal tumors “hot”
  • VB-111 is the first VTS-based therapy targeting the tumor vasculature for cancer therapies. The addition of nivolumab to the therapy may synergize the anti-tumor effect of VB-111

Click here ­to­ read full press release/ article | Ref: VBL | Image: VBL


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions